Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2013 | review | Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013

Chronic myelomonocytic leukaemia: diagnosis and therapeutic implications

memo - Magazine of European Medical Oncology > Ausgabe 1/2013
MD Sonja Burgstaller


Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of the haematopoietic stem cell characterised by the presence of an absolute monocytosis in peripheral blood. The disease carries myelodysplastic and myeloproliferative features. This dilemma was sought to be overcome by the World Health Organization (WHO) in 2001, when CMML was classified within a new category of myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN). The identification of molecular markers in patients with CMML has dramatically increased over the past couple of years. However, the impact on prognosis and therapeutic interventions needs to be defined. Testing of new agents in the setting of CMML proves to be difficult due to limited number of patients. This review has a focus on current diagnosis including new molecular data and treatment of CMML.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2013

memo - Magazine of European Medical Oncology 1/2013 Zur Ausgabe